STANDARD RISK B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA

标准风险 B 前体急性淋巴细胞白血病

• 批准号: 7607542
• 负责人: YOUSIF H MATLOUB
• 金额: $ 1.52万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607542
• 关键词: Acute Lymphocytic Leukemia; Cancer Cell Growth; Chemotherapy-Oncologic Procedure; Clinical Trials; Combination Chemotherapy; Computer Retrieval of Information on Scientific Projects Database; Databases; Drug Combinations; Drug usage; Funding; Grant; Institution; National Cancer Institute; Newly Diagnosed; Patients; Phase III Clinical Trials; Physician Data Query; Randomized; Research; Research Personnel; Resources; Risk; Source; Standards of Weights and Measures; United States National Institutes of Health; Work; cancer cell; cell killing; chemotherapy; killings

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. (Clinical trial summary from the National Cancer Institute's PDQ¿ database) Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. This randomized Phase III trial is studying different combination chemotherapy regimens and comparing how well they work in treating patients with newly diagnosed acute lymphoblastic leukemia.

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 （临床试验总结来自国家癌症研究所的PDQ数据库） 化疗中使用的药物以不同的方式阻止癌细胞的生长，要么杀死细胞，要么阻止它们分裂。给予一种以上的药物（联合化疗）可能会杀死更多的癌细胞。 这项随机III期试验正在研究不同的联合化疗方案，并比较它们在治疗新诊断的急性淋巴细胞白血病患者中的效果。